Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT …

F Costa, D Van Klaveren, S James, D Heg, L Räber… - The Lancet, 2017 - thelancet.com
Background Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y 12 inhibitor prevents
ischaemic events after coronary stenting, but increases bleeding. Guidelines support …

Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial

M Valgimigli, A Gagnor, P Calabró, E Frigoli… - The Lancet, 2015 - thelancet.com
Background It is unclear whether radial compared with femoral access improves outcomes
in unselected patients with acute coronary syndromes undergoing invasive management …

[HTML][HTML] Dual antiplatelet therapy after PCI in patients at high bleeding risk

M Valgimigli, E Frigoli, D Heg, J Tijssen… - … England Journal of …, 2021 - Mass Medical Soc
Background The appropriate duration of dual antiplatelet therapy in patients at high risk for
bleeding after the implantation of a drug-eluting coronary stent remains unclear. Methods …

Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis

R Piccolo, GG Stefanini, A Franzone… - Circulation …, 2015 - Am Heart Assoc
Background—Although new-generation drug-eluting stents represent the standard of care
among patients undergoing percutaneous coronary intervention, there remains debate …

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin …

P Vranckx, M Valgimigli, P Jüni, C Hamm, PG Steg… - The Lancet, 2018 - thelancet.com
Background We hypothesised that ticagrelor, in combination with aspirin for 1 month,
followed by ticagrelor alone, improves outcomes after percutaneous coronary intervention …

Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized …

L Räber, Y Ueki, T Otsuka, S Losdat, JD Häner… - Jama, 2022 - jamanetwork.com
Importance Coronary plaques that are prone to rupture and cause adverse cardiac events
are characterized by large plaque burden, large lipid content, and thin fibrous caps. Statins …

[HTML][HTML] Bivalirudin or unfractionated heparin in acute coronary syndromes

M Valgimigli, E Frigoli, S Leonardi… - … England Journal of …, 2015 - Mass Medical Soc
Background Conflicting evidence exists on the efficacy and safety of bivalirudin
administered as part of percutaneous coronary intervention (PCI) in patients with an acute …

Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease …

GG Stefanini, B Kalesan, PW Serruys, D Heg… - The Lancet, 2011 - thelancet.com
Background The effectiveness of durable polymer drug-eluting stents comes at the expense
of delayed arterial healing and subsequent late adverse events such as stent thrombosis …

Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the …

L Raeber, H Kelbaek, M Ostojic, A Baumbach, D Heg… - Jama, 2012 - jamanetwork.com
Context The efficacy and safety of drug-eluting stents compared with bare-metal stents
remains controversial in patients with ST-segment elevation myocardial infarction (STEMI) …

P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials

M Valgimigli, F Gragnano, M Branca, A Franzone… - Bmj, 2021 - bmj.com
Objective To assess the risks and benefits of P2Y 12 inhibitor monotherapy compared with
dual antiplatelet therapy (DAPT) and whether these associations are modified by patients' …